thrombomodulin alfa
Recombinant proteinexperimental
Clinical trial activity
9 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
7
Phase 3
3
Phase 4
1
Earliest trial started Jul 1, 2007 (NCT00487656)
Timeline
Indications
Approved for
Mechanism of action
- Vitamin K-dependent protein CACTIVATOR
PROC activator
- ThrombinINHIBITOR
F2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108653 ↗
Also known as
- art123
- art-123
- art-123
- art-123
- thrombomodulin alfa
- thrombomodulin alfa
- thrombomodulin (human 498-amino acid fragment)
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05251727 | Phase 1 | Mar 24, 2022 | Veloxis Pharmaceuticals |
| NCT04492436 | Phase 2 | Nov 30, 2020 | Asahi Kasei Pharma |
| NCT03517501 | Phase 3 | Jul 31, 2018 | Asahi Kasei Pharma |
| NCT02792842 | Phase 2 | Jul 1, 2016 | Asahi Kasei Pharma |
| NCT02739165 | Phase 3 | May 1, 2016 | Asahi Kasei Pharma |
| NCT01704001 | Phase 4 | Oct 1, 2012 | Asahi Kasei Pharma |
| NCT01598831 | Phase 3 | Aug 1, 2012 | Asahi Kasei Pharma |
| NCT01090115 | Phase 2 | Mar 1, 2008 | Artisan Pharma, Inc., University of South Alabama |
| NCT00487656 | Phase 2 | Jul 1, 2007 | Artisan Pharma, Inc. |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Asahi Kasei Pharma | For profit | 6 | 6 | 3 | 2012 |
| Artisan Pharma, Inc. | For profit | 2 | 1 | 1 | 2007 |
| University of South Alabama | Academic/Hospital | 1 | 1 | 1 | 2008 |
| Veloxis Pharmaceuticals | For profit | 1 | 1 | 1 | 2022 |
4 organizations
Page 1 / 1